Home Compare ABBV vs GILD
Stock Comparison · Industry comparison · Drug Manufacturers - General

AbbVie vs Gilead Sciences: Which Stock Looks Stronger in 2026?

Gilead Sciences holds the cleaner structural position, with the lead spread across valuation and profitability. AbbVie still has the edge on growth, which keeps the comparison from looking entirely one-sided. On the market side, Gilead Sciences is in better shape — its trend is intact while AbbVie's trend has broken down. That puts structure and market broadly in agreement — Gilead Sciences's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in valuation, with profitability adding a second layer of support. The overall score gap is 26 points in favour of Gilead Sciences, Inc..

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. ABBV and GILD share the same industry classification.

For a similarity-based comparison, see how AbbVie and Gilead Sciences each position within their functional peer groups in AssetNext.

Peer-Relative Score
ABBV
AbbVie Inc.
44
Peer-Score
Signal qualityHigh
vs
GILD
Gilead Sciences, Inc.
70
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing and operating quality both support the lead here.

Dimension spread: ABBV vs GILD Profitability 40 79 Stability 68 65 Valuation 19 83 Growth 62 44 ABBV GILD
Gap Ranking
#1 Valuation +64
#2 Profitability +39
#3 Growth +18
#4 Stability +3
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ABBV and GILD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ABBVGILD Relative valuation Structural strength

The two profiles are relatively close, but the price setup still leans toward Gilead Sciences, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
On valuation, Gilead Sciences, Inc. ranks near the top of the group; AbbVie Inc. sits in the weaker half.
Profitability
On profitability, the same pattern holds: both are strong, but Gilead Sciences, Inc. still leads clearly.
Valuation — Dominant Gap
ABBV
19
GILD
83
Gap+64in favour of GILD

The multiple-based pricing edge comes from a trailing P/E that is 68 turns lower.

What else supports the lead

Capital efficiency adds support, with a 14.2-point ROIC advantage.

What this means for the comparison

The lead is built on both valuation and profitability — though growth still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the ABBV vs GILD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-and-profitability comparisons

Explore how ABBV and GILD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.